Project Grant K99CA286761
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$258K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $125,783.00 to The University of Texas MD Anderson Cancer Center to conduct research on advanced gastric adenocarcinoma (GAC). The key objectives are to: 1) Determine the mechanisms of CDH1-inactivated advanced GAC progression, focusing on the roles of SOX4 and EZH2; and 2) Evaluate molecular subtype-based responses to immune checkpoint blockade. The research leverages murine organoid...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the effects of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research aims to understand how NRF2 activation impacts LUSC initiation, progression, and the tumor microenvironment using a novel genetically-engineered mouse model. The University of Washington will perform multi-omics...
The National Cancer Institute (NCI) awarded a $136,266 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The grant supports research to determine mechanisms by which inactivating the EED protein can block the transformation of lung adenocarcinoma (LUAD) into small cell lung cancer (SCLC), a common resistance mechanism to EGFR inhibitor therapies. The research aims to 1) understand how EED inactivation promotes...
This Project Grant award of $230,010 from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to unravel the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The award was granted to the University of Chicago and will run from March 1, 2025 to February 28, 2027. The research integrates human pluripotent stem cell-derived SCLC models, clinical samples, and patient-derived...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675.00 to The University of Texas Southwestern Medical Center to conduct research on innovative therapeutic strategies for small cell lung cancer (SCLC). The research aims to investigate the role of Jumonji demethylases as potential druggable targets in SCLC, including evaluating the impact of Jumonji inhibitors on SCLC growth and therapeutic resistance. The project will...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $563,233 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Medical University of South Carolina. The 5-year grant, which commenced on April 1, 2025, supports research to investigate how the sphingosine kinase 2 (SPHK2)/sphingosine-1-phosphate (S1P) axis regulates the immunosuppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The key objectives...
The National Cancer Institute (NCI) awarded a 5-year, $646,739 Project Grant (CFDA 93.396 - Cancer Biology Research) to Cedars-Sinai Medical Center to investigate the role of hepatic stellate cells (HSCs) in promoting liver metastasis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The research aims to elucidate the regulatory mechanisms and functional roles of extra-tumoral and intra-tumoral HSCs, as well as the impact of extracellular matrix (ECM)...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...